Click to view the official SEC document.

Click to view the official SEC document.

YouTube video by SWWK CH2

Precision BioSciences (Nasdaq: DTIL), a clinical-stage gene editing company, announced it will publish its second quarter 2026 financial results and provide a business update on Thursday, August 6, 2026.According to Precision BioSciences, its proprietary ARCUS genome editing platform is designed for smaller size, simpler structure, and distinct cutting properties to support sophisticated in vivo gene edits. The pipeline includes clinical-stage candidates such as PBGENE-HBV for viral DNA elimination and PBGENE-DMD for gene excision using dual ARCUS nucleases delivered in a single AAV.

Precision BioSciences (NASDAQ: DTIL) announced initial results from the ELIMINATE-B Phase 1 trial of PBGENE-HBV, their novel gene editing therapy for chronic Hepatitis B. The first cohort of three patients received the lowest dose level (0.2 mg/kg) of PBGENE-HBV, which uses ARCUS-encoding mRNA in lipid nanoparticles.Key findings include:The treatment was safe and well-tolerated with no Grade ≥2 treatment-related adverse eventsTwo of three participants showed substantial reduction in Hepatitis B surface antigen (HBsAg)The trial is designed for three dose administrations per dose levelThe study is currently enrolling HBeAg-negative chronic Hepatitis B patients in Moldova, Hong Kong, and New Zealand, with plans to expand to the U.S. and U.K. Precision plans to share detailed clinical data throughout 2025.

Pioneering ARCUS® gene editing therapy targets chronic hepatitis B virus across all genotypes. Phase 1 ELIMINATE-B trial expands with second regulatory approval of 2024.

Using AI to find stock market opportunities.

Profit on the stock market by investing in biotech stocks

Investigators say air traffic controllers missed Marine One’s takeoff warning before it nearly collided with a passenger jet

iECURE (DTIL)/b) reported updated clinical data from the ongoing Phase 1/2 trial of gene-insertion therapy ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency, presented at the SSIEM 2026 symposium. According to iECURE, dosing is complete in all three cohorts (low, intermediate, high), with nine participants treated.As of July 28, 2026, ECUR-506 was generally well tolerated across dose levels, with no unexpected treatment-related safety events, thrombotic microangiopathy, or infusion reactions. In the low-dose cohort, annualized hyperammonemic events were reduced by 57% (p=0.02) and hyperammonemic crises by 74% (p=0.01) versus pre-treatment. Liver biopsies in two low-dose participants and serum PCSK9 reductions supported targeted hepatic editing. One participant achieved a complete clinical response, discontinuing ammonia scavengers and protein restriction, while the other two showed clinical improvements.

Click to view the official SEC document.

Precision BioSciences (Nasdaq: DTIL) has dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo ARCUS-based gene-editing therapy for Duchenne muscular dystrophy (DMD). The first dosing occurred at Arkansas Children’s Hospital, a certified Duchenne and MDA care center.PBGENE-DMD uses two ARCUS nucleases delivered in a single AAV vector to excise exons 45-55 of the dystrophin gene, aiming to enable endogenous production of near full-length functional dystrophin. According to Precision BioSciences, this design could be applicable to up to 60% of DMD patients with mutations in this hotspot region.The FUNCTION-DMD study is currently enrolling ambulatory boys aged 2–7 years with mutations between exons 45 and 55 at multiple specialized U.S. Duchenne care centers, with initial safety data targeted by year-end 2026.